ClinicalTrials.gg
Not yet recruitingNCT05910125AGREEUpdated Jun 18, 2023

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

A Phase 4 interventional study of Aspirin and Clopidogrel in Ischemic Stroke, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing aspirin in Ischemic Stroke — 7 open to participants now, 7 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.

Planned enrollment
10th of 23
472 · median 400
Started
2023
with 1 other
Phase 4
10 of 23
3 open now
Registered
16th of 23
by date

Among the 23 studies testing aspirin in Ischemic Stroke, this one is the 10th largest by planned enrollment, is one of 2 that started in 2023, is one of 10 in phase 4, and was the 16th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 23 studies testing aspirin in Ischemic Stroke are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing aspirin in Ischemic Stroke, or all of them as a file.
02

Study summary

An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 40-80 years.
  2. Diagnosed with acute ischemic stroke, NIHSS ≤ 5 and single item score ≤ 1 for vision, language, single limb, and no impairment of consciousness.
  3. Time from symptoms onset to randomization within 4.5 hours; the onset time refers to the "Last Known Normal" (LKN).
  4. Absence of large vessel occlusion on CTA.
  5. Pre-stroke mRS ≤ 1.
  6. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Clinically confirmed valvular or non-valvular atrial fibrillation requiring anticoagulation therapy.
  2. Intracranial hemorrhage or subarachnoid hemorrhage suggested by CT scan.
  3. Acute coronary syndrome suggested by .
  4. History of gastrointestinal bleeding.
  5. Planned sequential IVT or endovascular treatment.
  6. History of allergy to aspirin, clopidogrel, and/or alteplase.
  7. Systolic blood pressure exceeding 185 mmHg and/or diastolic blood pressure exceeding 110 mmHg despite antihypertensive treatment.
  8. Blood glucose ≤ 2.7 mmol/L.
  9. Epileptic seizures during a stroke attack.
  10. Recent trauma (\<15 days).
  11. Recent intracranial or spinal cord surgery, head trauma, or stroke (\<3 months).
  12. History of intracranial hemorrhage, aneurysm, vascular malformation, or brain tumor.
  13. Active visceral hemorrhage (\<22 days).
  14. History of anticoagulant use within 24 hours prior to onset.
  15. \<100,000, > 40 seconds on heparin, or PT > 15 or INR > 1.7, or known bleeding disposition.
  16. Anticipated \< 3 months.
  17. Pregnant or lactating women.
  18. Participation in other clinical trials.
  19. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
472 participants (estimated)

Study arms

  • Experimental
    DAPT group

    Receiving dual antiplatelet therapy immediately after randomization (Oral aspirin 100mg+clopidogrel 300mg, Day 1). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90) and clopidogrel 75mg/d (Day 2-21), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.

    Drug: Aspirin · Drug: Clopidogrel

  • Active comparator
    IVT group

    Receiving intravenous thrombolysis immediately after randomization (Intravenous alteplase, 0.9mg/kg, a maximum dosage of 90mg). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.

    Drug: Alteplase

Interventions

06

What researchers measure

Primary outcomes

  1. The modified Rankin Scale score (mRS) 0-1

    The proportion of the modified Rankin Scale score (mRS) 0-1 at 90 days.

    Time frame: 90(±7) days

Secondary outcomes

  1. The modified Rankin Scale score (mRS) 0-1

    The proportion of the modified Rankin Scale score (mRS) 0-1 at 7 days or discharge (whichever occurred first).

    Time frame: 7(±1) days

  2. Early neurological deterioration

    The incidence of early neurological deterioration at 7 days.

    Time frame: 7(±1) days

  3. Recurrent stroke

    The incidence of recurrent stroke at 90 days.

    Time frame: 90(±7) days

Other outcomes

  1. SAFETY OUTCOME: Symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage within 36 hours (according to Heidelberg criteria)

    Time frame: 24 (±12) hours

  2. SAFETY OUTCOME: Mortality

    Mortality at 90 days

    Time frame: 90(±7) days

  3. SAFETY OUTCOME: Any intracranial hemorrhage

    Any intracranial hemorrhage within 36 hours (according to Heidelberg criteria)

    Time frame: 24 (±12) hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Jul 2027, 48 months later.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 48 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2023
First posted
Jun 18, 2023
StartEst.
Jul 2023
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05910125
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 2023 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 18, 2023

Study contacts

Yamei Tang
Contact
tangym@mail.sysu.edu.cn
86-20-81332619
Yamei Tang
principal investigator · Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel

Start the discussion